LifeStance Health Group, Inc. (NASDAQ:LFST – Get Free Report) Director Robert Bessler sold 575,034 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total value of $4,611,772.68. Following the transaction, the director directly owned 986,931 shares in the company, valued at $7,915,186.62. This represents a 36.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Robert Bessler also recently made the following trade(s):
- On Thursday, May 7th, Robert Bessler sold 75,000 shares of LifeStance Health Group stock. The stock was sold at an average price of $8.55, for a total value of $641,250.00.
- On Friday, April 24th, Robert Bessler sold 62,147 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.05, for a total value of $438,136.35.
- On Thursday, April 23rd, Robert Bessler sold 7,752 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total transaction of $54,264.00.
- On Tuesday, April 21st, Robert Bessler sold 5,101 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.01, for a total transaction of $35,758.01.
LifeStance Health Group Stock Performance
LifeStance Health Group stock traded down $0.21 during mid-day trading on Thursday, reaching $7.89. 5,260,978 shares of the company traded hands, compared to its average volume of 3,283,413. The firm’s fifty day moving average is $6.86 and its two-hundred day moving average is $6.76. The company has a market capitalization of $3.06 billion, a price-to-earnings ratio of 131.50 and a beta of 1.20. LifeStance Health Group, Inc. has a fifty-two week low of $3.74 and a fifty-two week high of $8.89. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.48 and a quick ratio of 1.65.
LifeStance Health Group announced that its board has approved a share buyback program on Wednesday, February 25th that permits the company to buyback $100.00 million in shares. This buyback authorization permits the company to buy up to 3.6% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.
Analyst Ratings Changes
Several analysts have recently commented on the stock. UBS Group upped their price objective on shares of LifeStance Health Group from $10.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, February 26th. BTIG Research increased their price target on LifeStance Health Group from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Weiss Ratings raised LifeStance Health Group from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, February 27th. Zacks Research upgraded LifeStance Health Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 27th. Finally, Jefferies Financial Group raised LifeStance Health Group to a “strong-buy” rating in a report on Thursday, March 12th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $9.86.
View Our Latest Stock Analysis on LFST
Institutional Investors Weigh In On LifeStance Health Group
A number of institutional investors have recently modified their holdings of LFST. Royal Bank of Canada increased its stake in shares of LifeStance Health Group by 63.4% in the 1st quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock valued at $468,000 after purchasing an additional 27,244 shares in the last quarter. AQR Capital Management LLC boosted its position in LifeStance Health Group by 223.0% during the first quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock worth $343,000 after purchasing an additional 35,554 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in LifeStance Health Group by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock valued at $952,000 after purchasing an additional 4,169 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in LifeStance Health Group by 1.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock valued at $4,100,000 after purchasing an additional 11,331 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of LifeStance Health Group by 10.2% in the second quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company’s stock valued at $2,847,000 after buying an additional 51,154 shares in the last quarter. 85.50% of the stock is currently owned by institutional investors and hedge funds.
About LifeStance Health Group
LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.
The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.
Read More
- Five stocks we like better than LifeStance Health Group
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
